Tumor-specific immunotherapy of murine bladder cancer with butanol-extracted antigens and ethylchlorformate polymerized tumor protein.
Successful treatment of superficial bladder cancer using nonspecific immunotherapy with Bacillus Calmette-Guerin (BCG) has been well documented. Investigation of two potential tumor-specific immunotherapeutic agents using a murine transitional-cell carcinoma model (MBT-2) is reported. The survival of mice immunized with tumor proteins obtained by treating tumor cells with either 1-butanol or ethylchlorformate was compared to the survival of animals immunized with BCG. Long-term immunity conferred by each of these agents was also assessed. Significant protection by both agents was noted in all treatment groups compared to controls. Long-term immunity was also found to result from treatment with both investigational agents as well as with BCG. Butanol-extracted antigens and ethylchlorformate polymerized tumor protein may be useful as immunotherapeutic alternatives to BCG.
Rochester
M G
MG
Division of Urology, University of Texas Health Science Center, San Antonio.
Sarosdy
M F
MF
Pickett
S H
SH
Stogdill
B J
BJ
Lamm
D L
DL
D000818:Animals; D000951:Antigens, Neoplasm / Q000008:administration & dosage*; D001500:BCG Vaccine / Q000627:therapeutic use; D000440:Butanols; D002295:Carcinoma, Transitional Cell / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D005561:Formates; D005563:Formic Acid Esters; D051379:Mice; D008809:Mice, Inbred C3H; D009363:Neoplasm Proteins / Q000627:therapeutic use*; D011108:Polymers; D001749:Urinary Bladder Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*
D000951:Antigens, Neoplasm; D001500:BCG Vaccine; D000440:Butanols; D005561:Formates; D005563:Formic Acid Esters; D009363:Neoplasm Proteins; D011108:Polymers; C007658:ethyl chloroformate